A recently completed phase I clinical trial of intratumoral TLR4 agonist G100 in ten patients with advanced Merkel cell carcinoma also showed promising results with partial and complete responders during a median follow up of 33 months, in conjunction with histologic evidence of increased cytotoxic immune cell infiltration (42). Here, TLR4 is linked to Merkel cell skin cancer.